Skip to content
ApprovedFDA approvedStrong evidence

Vortioxetine

Prescription antidepressant for major depression in adults that may also help with concentration difficulties.

AntidepressantSerotonin modulatorAntidepressantMoodSerotoninDopaminenoo.affects.moodnoo.affects.memory
Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Pharmacology

ClassAntidepressant · Mood
Primary targetSerotonin transporter (SERT) inhibition + multimodal 5-HT receptor modulation
Targets4 receptor targets
Half-lifeAbout 66 hours, which allows once-daily dosing
OnsetDepressive symptoms typically begin improving after 1-2 weeks, with full effect taking 4-6 weeks
EvidenceStrong evidence
Affected systemsSerotoninDopaminenoo.affects.moodnoo.affects.memory

Contents

DETAILED OVERVIEW

What is Vortioxetine?

Vortioxetine is a prescription antidepressant approved for major depression in adults in the United States (Trintellix) and in the European Union (Brintellix). It is not a dietary supplement.

It acts on the serotonin system in several ways: it blocks the reuptake of serotonin and directly alters several serotonin receptors. In studies, besides mood it also improved the concentration and thinking difficulties that accompany depression, and sexual side effects were less common than with conventional antidepressants known as SSRIs. The most common side effect is nausea, mainly in the first weeks of treatment, which then eases. It must not be combined with medicines called MAO inhibitors because of the risk of serotonin syndrome (a dangerous excess of serotonin). In people under 25 the risk of suicidal thoughts can be higher at the start of treatment, which is a shared feature of antidepressants. In pregnancy and breastfeeding it can be used only after a doctor has weighed benefit and risk.

Mechanism

Blocks serotonin reuptake; modulates several serotonin receptors

Half-life

~66 hours (once-daily dosing)

Legal status

Prescription antidepressant (FDA/EMA approved)

Receptor profile

  • Serotonin transporter (SERT)Strong
  • 5-HT3 / 5-HT7 / 5-HT1D receptor antagonismStrong
  • 5-HT1A receptor agonismModerate
  • 5-HT1B receptor partial agonismModerate

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Nausea, the most common side effect, typically in the first weeks of treatment and gradually easing
  • Diarrhea, constipation or vomiting, usually mild and transient
  • Dizziness, dry mouth and itching
  • Sexual dysfunction, though typically to a lesser degree than with conventional SSRIs
  • Hyponatremia (low blood sodium), especially in the elderly and those on diuretics
  • Rarely serotonin syndrome, especially combined with other serotonergic agents

Contraindications · 5

  • Co-administration with MAO inhibitors is contraindicated due to serotonin syndrome risk (14-day washout required)
  • Known hypersensitivity to vortioxetine or any excipient of the product
  • Extra caution in patients under 25 due to the early risk of suicidal ideation (class effect)
  • History of mania/hypomania or bipolar disorder: an antidepressant may trigger a mood switch
  • Pregnancy and breastfeeding: only after clear benefit-risk assessment under medical supervision

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Vortioxetine is a prescription antidepressant used to treat major depression in adults. Beyond lifting mood, it can also help with the thinking and concentration problems that often come with depression, and tends to cause fewer sexual side effects than older SSRIs. It has also been studied and approved for use in older adults.

Telegram

Have a question about Vortioxetine?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeAntidepressant
FormulaC18H22N2S
UpdatedOctober 14, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.